Health Care·Biotechnology·$5.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.50 | N/A | -17.74% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-1.50 | N/A | -17.74% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Overall, management expressed concerns about recent performance while highlighting their commitment to future growth initiatives.
Management acknowledged the challenges faced during the quarter.
They emphasized a focus on long-term strategies despite current setbacks.
The earnings report indicates that PTC Therapeutics is facing challenges, particularly reflected in their EPS miss. The stock's slight decline of 0.13% suggests that investors may be cautious about the company's current trajectory. Without revenue figures or updated guidance, uncertainty remains about the company's short-term outlook.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
CENTERPOINT ENERGY I
Feb 26, 2016